Is	O
the	O
Major	O
Determinant	O
of	O
Plasma	B:C0032105
Ghrelin	B:C0911014
Level	O
in	O
Hemodialysis	B:C0019004
Patients	O
.	O

Ghrelin	B:C0911014
,	O
an	O
orexigenic	B:C0019932
hormone	I:C0019932
,	O
has	O
multiple	O
favorable	O
functions	O
including	O
protein	B:C0597295
anabolism	I:C0597295
enhancement	O
,	O
anti-inflammatory	O
actions	O
,	O
and	O
cardiovascular	B:C3887460
protection	O
.	O

A	O
low	O
plasma	B:C0032105
ghrelin	B:C0911014
level	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
patients	O
treated	B:C0332293
with	I:C0332293
hemodialysis	B:C0019004
(	O
hemodialysis	B:C0019004
)	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
plasma	B:C0032105
ghrelin	B:C0911014
level	O
in	O
hemodialysis	B:C0019004
patients	O
correlates	O
with	O
the	O
severity	O
of	O
gastric	O
mucosal	O
atrophy	O
and	O
Helicobacter	B:C0079488
pylori	I:C0079488
status	O
.	O

Seventy	O
-	O
eight	O
maintenance	O
hemodialysis	B:C0019004
patients	O
and	O
51	O
non-dialysis	O
patients	O
with	O
chronic	B:C1561643
kidney	I:C1561643
disease	I:C1561643
were	O
evaluated	B:C0220825
for	O
severity	O
of	O
gastric	O
mucosal	O
atrophy	O
by	O
gastroduodenoscopy	B:C0192657
and	O
for	O
H.	B:C0079488
pylori	I:C0079488
status	O
using	O
an	O
anti-H.	B:C0373906
pylori-antibody	I:C0373906
and	O
rapid	O
urease	B:C0585237
test	I:C0585237
.	O

Plasma	B:C0032105
acyl	B:C0911014
and	O
des-acyl	B:C0965048
ghrelin	I:C0965048
levels	O
were	O
measured	O
and	O
their	O
associations	O
with	O
relevant	O
clinical	O
parameters	B:C0449381
were	O
investigated	O
.	O

Des	B:C0965048
-	I:C0965048
acyl	I:C0965048
ghrelin	I:C0965048
level	O
in	O
hemodialysis	B:C0019004
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
kidney	B:C0232804
function	I:C0232804
preserved	O
.	O

Although	O
acyl	B:C0911014
and	O
des-acyl	B:C0965048
ghrelin	I:C0965048
levels	O
were	O
similar	O
between	O
current	O
H.	B:C0079488
pylori	I:C0079488
positive	O
and	O
negative	O
hemodialysis	B:C0019004
patients	O
,	O
both	O
levels	O
decreased	O
significantly	O
with	O
the	O
progress	O
of	O
endoscopic	O
gastric	O
mucosal	O
atrophy	O
in	O
hemodialysis	B:C0019004
patients	O
.	O

Serum	B:C0443461
pepsinogen	I:C0443461
(	O
pepsinogen	B:C0443461
)	O
I	B:C0443461
level	O
and	O
PG	B:C0443461
I	I:C0443461
/	O
II	B:C0030913
ratio	O
decreased	O
significantly	O
according	O
to	O
the	O
severity	O
of	O
atrophy	O
in	O
hemodialysis	B:C0019004
patients	O
and	O
positively	O
significantly	O
correlated	O
with	O
both	O
ghrelin	B:C0911014
levels	O
.	O

Multiple	B:C0034980
regression	I:C0034980
analysis	I:C0034980
showed	O
significant	O
positive	O
correlations	O
between	O
acyl	B:C0911014
ghrelin	I:C0911014
and	O
PG	B:C0443461
I	I:C0443461
levels	O
(	O
Î²	O
=	O
0.738	O
,	O
p	O
<	O
0.001	O
)	O
and	O
significant	O
negative	O
correlations	O
between	O
ghrelin	B:C0911014
and	O
age	O
,	O
albumin	B:C0001924
,	O
and	O
creatinine	B:C0010294
levels	O
.	O

Gastric	B:C0017154
atrophy	I:C0017154
is	O
the	O
major	O
determinant	O
of	O
ghrelin	B:C0911014
level	O
in	O
hemodialysis	B:C0019004
patients	O
.	O

Management	O
practices	O
,	O
such	O
as	O
H.	B:C0559761
pylori	I:C0559761
eradication	I:C0559761
,	O
before	O
advanced	O
atrophy	B:C0017154
may	O
be	O
required	O
to	O
prevent	O
the	O
decrease	O
of	O
ghrelin	B:C0911014
levels	O
and	O
improve	O
the	O
prognosis	B:C0278250
of	O
hemodialysis	B:C0019004
patients	O
.	O

